Pages that link to "Q40242694"

The following pages link to CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice (Q40242694):

Displaying 32 items.

• Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms (Q26795594) (← links)
• Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice (Q27654979) (← links)
• Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. (Q27851612) (← links)
• FGFR3 Is Overexpressed Waldenström Macroglobulinemia and Its Inhibition by Dovitinib Induces Apoptosis and Overcomes Stroma-Induced Proliferation (Q28236353) (← links)
• Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias (Q28252023) (← links)
• Recent advances in antimultiple myeloma drug development (Q33416297) (← links)
• Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration. (Q33783047) (← links)
• Targeted therapies for adrenocortical carcinoma: IGF and beyond (Q34101433) (← links)
• FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells (Q34542012) (← links)
• Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors (Q34704781) (← links)
• The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). (Q35018563) (← links)
• Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts (Q36395148) (← links)
• Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis. (Q36555872) (← links)
• UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression (Q36562144) (← links)
• Maintenance therapy in multiple myeloma (Q36754178) (← links)
• Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials. (Q36844954) (← links)
• From the bench to the bedside: emerging new treatments in multiple myeloma (Q37028598) (← links)
• The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors (Q37061044) (← links)
• New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. (Q37336468) (← links)
• The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer (Q37389768) (← links)
• Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. (Q37415946) (← links)
• Targeting mutant fibroblast growth factor receptors in cancer (Q37849013) (← links)
• Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. (Q37849781) (← links)
• Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. (Q38056889) (← links)
• Understanding the molecular biology of myeloma and its therapeutic implications (Q38065305) (← links)
• Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation (Q38268782) (← links)
• Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma (Q39593507) (← links)
• The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies (Q42155683) (← links)
• A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells (Q42734250) (← links)
• Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia (Q47612372) (← links)
• The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer (Q50085302) (← links)
• Clinical and biological features of t(4;14) multiple myeloma: a prospective study (Q57217664) (← links)